Project Grant R01NS146233
- The National Institute of Neurological Disorders and Stroke awarded The Washington University $618,108 on June 18, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to conduct research on neuroinflammation in cerebral small vessel disease, a leading vascular contributor to cognitive impairment and dementia. The recipient will evaluate the relationship between 11C-CS1P1 PET uptake—a novel positron emission tomography radiotracer...
- The National Institute of Neurological Disorders and Stroke awarded The Washington University $155,500 on June 1, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to map mitochondrial NADPH utilization by exploiting hypomorphic variants of NADK2. The award funds generation of cell lines harboring disease-associated NADK2 variants and functional assessment of those variants to illuminate how mitochondrial NADPH is allocated...
- The National Institute of Neurological Disorders and Stroke awarded the University of Missouri System $329,234 on June 15, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to support research on synaptic function during metabolic stress. The research project, titled "Transforming Synapses to Operate During Extreme Metabolic Dysfunction," investigates how the brain maintains synaptic performance when energy delivery...
- The National Institute of Neurological Disorders and Stroke awarded Vanderbilt University Medical Center $444,336 on September 1, 2026, to establish and validate integrated imaging biomarkers for multiple system atrophy (MSA) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). The project develops and validates MRI-based biomarkers to improve diagnosis and enable monitoring of disease progression in patients with MSA, a rare, progressive,...
- The National Institute of Neurological Disorders and Stroke awarded New York University $247,300 on July 14, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to develop quantitative MRI methods for assessing white matter injury and repair. The project integrates multi-shell, multi-diffusion time MRI with large-scale three-dimensional electron microscopy and quantitative immunofluorescence to establish how diffusion and T2-based...
- The National Institute of Neurological Disorders and Stroke, part of the Department of Health and Human Services National Institutes of Health, awarded $544,568 to Cleveland Clinic Lerner College of Medicine of Case Western Reserve University on February 11, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to investigate the pathogenesis of permanent neurological disability in multiple sclerosis. The research identifies cellular...
- The National Institute of Neurological Disorders and Stroke awarded The Washington University $618,077 on June 1, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to develop next-generation tools for human cortical cartography. The award funds generation of a multi-modal atlas of human cortical areas with improved accuracy beyond the 2016 version, characterization of individual variability and subareal organization within cortical...
- The National Institute of Biomedical Imaging and Bioengineering awarded The Washington University $119,818 on July 1, 2026, under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) to develop AI-powered gradient echo plural contrast imaging (AI-GEPCI) technology for early detection and monitoring of progressive multiple sclerosis. The award funds development of an integrated neuroimaging platform that combines deep learning with...
- The National Institute of Neurological Disorders and Stroke awarded the University of Illinois $407,211 on August 21, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to conduct research on neural progenitor cell differentiation and therapeutic mechanisms in multiple sclerosis. The research investigates a natural product-derived Notch1 signaling inhibitor, (+)-3D-spiro-oxindole, designed to promote neural progenitor and stem...
- The National Institute of Neurological Disorders and Stroke awarded Massachusetts Institute of Technology $651,069 on May 2, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to develop spatially multiplexed imaging techniques for visualizing complex signaling networks in neurons and brain cells. The research advances a method called Signaling Reporter Islands (SIRIs) that enables simultaneous imaging of multiple cellular signals...
The National Institute of Neurological Disorders and Stroke awarded The Washington University $618,001 on September 1, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to develop and validate deuterium metabolic spectroscopy and imaging (DMS/I) as a technique for non-invasively measuring brain glucose and ketone metabolism in multiple sclerosis. The project uses deuterium-labeled metabolic tracers to investigate how energy substrate utilization varies across different stages of MS in preclinical models, from lesion formation through spontaneous recovery and therapeutic intervention. The work encompasses three primary aims: evaluating glucose metabolism during lesion formation and recovery, characterizing ketone body utilization as an alternative energy source during disease progression and repair, and assessing the potential of metabolic probes to monitor therapeutic efficacy. Ex vivo biochemical and histopathological analyses will validate the imaging findings. Performance occurs in St. Louis, Missouri, with a period of performance from September 1, 2026, through May 31, 2031. This is a Project Grant, the standard assistance type for investigator-initiated research under the NINDS extramural portfolio. The award addresses the unmet need for direct, quantitative imaging of cerebral metabolic processes that current structural MRI methods fail to capture, with potential application to disease outcome prediction and therapeutic response evaluation in MS.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $618.0k | 8/24/26 |